TECH OFFER

Novel Molecule Targeting ROR2 for the Promotion of Healthy Cartilage in Osteoarthritis

KEY INFORMATION

TECHNOLOGY CATEGORY:
Healthcare - Pharmaceuticals & Therapeutics
Chemicals - Bio-based
TECHNOLOGY READINESS LEVEL (TRL):
LOCATION:
United Kingdom
ID NUMBER:
TO155910

TECHNOLOGY OVERVIEW

Osteoarthritis (OA) is a debilitating joint disease characterized by breakdown of the articular cartilage and bone changes, including thickening of the bone supporting the cartilage and excessive bone formation at the margins of the joint (osteophytes). There are no disease modifying therapies to treat the cause of osteoarthritis. Current treatment consists of symptom management with non-steroidal-inflammatory drugs and eventually leads to joint replacement. Hence, there is an urgent unmet need for a new therapeutic approach targeting and resolving the aetiology of the disease.

TECHNOLOGY FEATURES & SPECIFICATIONS

This technology is a method of treatment of osteoarthritis which targets a novel cell-surface receptor named ROR2, that is specifically upregulated in cartilage as a result of local inflammation and mechanical stress. It is typically expressed in minimal level in physiological conditions.

Blockage of this receptor by siRNA, promotes cartilage repair which correlates with sustained pain relief, Fig 1A and 2A

Cartilage repair is achieved by:

  • Preventing cartilage degradation
    • inhibition of expression of key cartilage degrading enzymes
    • reduction in cartilage breakdown shown in vivo, Fig. 2A
    • Inducing cartilage formation
      • in vitro chondrogenic differentiation of a mesenchymal stem
        cell line
      • reduction in pathological growth of the medial tibia, Fig. 1B
      • increase in size and differentiation of human cartilage
        organoids, Fig 3

siRNA silencing of the target receptor in-vivo reduces cartilage breakdown in the meniscal/ligamentous injury model of osteoarthritis

Target receptor silencing supports formation of human cartilage organoids in vivo.

A composition of matter patent has been filed including both siRNA and peptide approaches against ROR2.

 

POTENTIAL APPLICATIONS

This method is targeting a non-redundant target with limited expression in adult tissues offering the advantage of fewer side effects compared to current anti-inflammatory therapies.

Benefits

  • Novel experimental treatment that eliminates pain and reverts structural changes in a murine model of osteoarthritis
  • Unique therapeutic potential: non-redundant target with limited expression in adult tissues offering the advantage of fewer side effects compared to current anti-inflammatory therapies
  • Inhibition of the proposed novel target can be developed into an effective therapy that can cure the cause of osteoarthritis, unlike current treatments that only ameliorate symptoms
RELATED TECH OFFERS
Therapeutic Inhibitor for Epstein-Barr Virus (EBV)-associated Cancers
Cancer Catcher - Early Detection of Circulating Tumour Cells
Potent Anti-bacterial Plant Oil for Skin Health and Ailment
Melanin Derived From Black Soldier Flies
Non-Invasive, Non-Toxic Encapsulation Technology to Prolong Effects of Leave-on Products
Novel Anti-microbial Agent for Preventing Dental Caries
Non-invasive Alzheimer’s Disease Diagnostic Kit
Growth Factor-free Proliferation & Differentiation of Stem Cell
A modified Chinese Medicine formulation for treating Alzheimer's disease
Plant-Harvested Biopolymer for Postsurgical Adhesion Barrier Gel and Film Application